Recursion Pharmaceuticals reported second quarter 2026 financial results showing total revenue of $7.7 million and a net loss of $131.0 million. The company reduced its full-year 2026 cash operating expense guidance to less than $375 million from $390 million, citing operational efficiencies. Genentech exercised the first Validated Target Option under its neuroscience collaboration with Recursion, advancing a previously unexplored target into an early discovery program. The company also announced that its IND for REC-7735, a PI3Kα H1047R inhibitor, was cleared, with Phase 1/2 trials expected to start in the second half of 2026. Recursion operates as a clinical-stage TechBio company using an AI-native platform to discover and develop therapeutic medicines.